{"id":"W4388524266","doi":"10.1183/13993003.02029-2022","title":"Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one<i>F508del</i>allele: 144-week interim results from a 192-week open-label extension study","year":2023,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Paul's Hospital; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Genentech; Grifols; Vertex Pharmaceuticals; Ionis Pharmaceuticals; Deutsches Zentrum für Infektionsforschung; Basilea Pharmaceutica; Insmed; Gilead Sciences; Shionogi; Arrowhead Pharmaceuticals; European Federation of Pharmaceutical Industries and Associations; Sanofi; Deutsches Zentrum für Lungenforschung; AstraZeneca; American Thoracic Society","keywords":"Ivacaftor; Discontinuation; Medicine; Tolerability; Interim; Adverse effect; Confidence interval; Interim analysis; Internal medicine; Cystic fibrosis; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002804382,0.0005055477,0.001115233,0.0006307359,0.0003905488,0.0002655289,0.0005935379,0.0000812104,0.0001004068],"category_scores_gemma":[0.001923277,0.000410102,0.00006830523,0.0008831209,0.0003789891,0.0004898803,0.001421727,0.001009185,0.00008456379],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002976027,"about_ca_system_score_gemma":0.0002693436,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009527124,"about_ca_topic_score_gemma":0.00009610574,"domain_scores_codex":[0.9940669,0.001386058,0.001529019,0.001069222,0.001175383,0.0007734067],"domain_scores_gemma":[0.9964117,0.0009901577,0.0006265715,0.0008290629,0.000346254,0.0007962922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.13428,0.007150915,0.5574065,0.0005090427,0.0007238417,0.009373171,0.001998866,0.000132931,0.2421271,0.00000478277,0.004034495,0.04225837],"study_design_scores_gemma":[0.03357909,0.01169148,0.9484246,0.002035261,0.0001569136,0.0003410729,0.0006621154,0.0001044701,0.0003985424,0.000004113924,0.002208709,0.0003935813],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957135,0.00203098,0.00008853433,0.0001080878,0.0000388957,0.00140798,0.0001723904,0.0000732205,0.0003663666],"genre_scores_gemma":[0.997057,0.0004333066,0.001274912,0.0001651639,0.0003041933,0.00001245756,0.00006391345,0.0001519762,0.0005371008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3910182,"threshold_uncertainty_score":0.9998351,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06974632485574715,"score_gpt":0.3339663486792207,"score_spread":0.2642200238234735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}